Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective

References

• Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011;34:1249-57
   PubMed Web of Science ®Google Scholar
• Temelkova-Kurktschiev T, Stefanov T. Lifestyle and genetics in obesity and type 2 diabetes. Exp Clin Endocrinol Diabetes 2012;120:1-6
   PubMed Web of Science ®Google Scholar
• Papier K, Jordan S, D'Este C, et al. Incidence and risk factors for type 2 diabetes mellitus in transitional Thailand: results from the Thai cohort study. BMJ Open. 2016;6:e014102
   Google Scholar
• Aekplakorn W. Prevalence and management of diabetes and associated risk factors by regions of Thailand, Third National Health Examination Survey 2004. Diabetes Care 2007;30:2007-12
   PubMed Web of Science ®Google Scholar
• Aekplakorn W, Stolk RP, Neal B, et al. The prevalence and management of diabetes in Thai adults: the international collaborative study of cardiovascular disease in Asia. Diabetes Care 2003;26:2758-63
   PubMed Web of Science ®Google Scholar
• Aekplakorn W, Chariyalertsak S, Kessomboon P, et al. Prevalence and management of diabetes and metabolic risk factors in Thai adults: the Thai National Health Examination Survey IV, 2009. Diabetes Care 2011;34:1980-5
   PubMed Web of Science ®Google Scholar
• Rawdaree P, Ngarmukos C, Deerochanawong C, et al. Thailand diabetes registry (TDR) project: clinical status and long term vascular complications in diabetic patients. J Med Assoc Thai 2006;89(Suppl1):S1-S9
   Google Scholar
• Bureau of Policy and Strategy, Ministry of Public Health, Thailand. Health Profile Report 2007–2013; August 25, 2015. http://bps2.moph.go.th/ 2015 Aug 25
   Google Scholar
• Diabetes Association of Thailand, The Endocrine Society of Thailand, Department of Medical Services Ministry of Public Health, National Health Security Office. Clinical Practice Guideline for Diabetes 2014. Bangkok Aroonkarnpim; 2014
   Google Scholar
• Home P, Fritsche A, Schinzel S, et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010;12:772-9
   PubMed Web of Science ®Google Scholar
• Guillermin A, Samyshkin Y, Wright D, et al. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. J Med Econ 2011;14:207-16
   PubMedGoogle Scholar
• Valentine W, Goodall G, Aagren M, et al. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modeling study of long-term clinical and cost outcomes. Adv Ther 2008;25:567-84
   PubMed Web of Science ®Google Scholar
• Yang L, Christensen T, Sun F, et al. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in chinese setting: a health economic model based on the PREDICTIVE study. Value Health 2012;15(1Suppl):S56-S9
   Web of Science ®Google Scholar
• Palmer A, Roze S, Valentine W, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (type 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl1):S5-S26
   Web of Science ®Google Scholar
• Palmer A, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl1):S27-S40
   Web of Science ®Google Scholar
• World Health Organization. Life tables by country: Thailand 2014. October 15, 2014. http://apps.who.int/gho/data/?theme=main&vid=61640 2014 Oct 15
   Google Scholar
• McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE Diabetes Model. Value Health 2014;17:714-24
   PubMed Web of Science ®Google Scholar
• The Endocrine Society of Thailand. Diabetes Registry Project 2003. Health Systems Research Institute; 2004 Bangkok
   Google Scholar
• Kosachunhanun N, Benjasuratwong Y, Mongkolsomlit S, et al Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. J Med Assoc Thai 2006;89(Supp1):S66-S71
   Google Scholar
• Rangsin R, Tatsanavivat P, MedResNet. An assessment on quality of care among patients diagnosed with type 2 diabetes and hypertension visiting hospitals of Ministry of Public Health and Bangkok Metropolitan Administration in Thailand, 2012. Thailand: National Health Security Office (NHSO); 2012 Bangkok
   Google Scholar
• National Statistical Office. Health 2007; October 15, 2014. http://web.nso.go.th/en/survey/bts/datafiles/560619_09_Health.pdf 2014 Oct 15
   Google Scholar
• Thamarangsi T. The situation of alcohol beaverage consumption and impact in Thailand 2013. Center for Alcohol Studies, International Health Policy Program, Ministry of Public Health; 2013 Bangkok
   Google Scholar
• Krairittichai U, Potisat S, Jongsareejit A, et al. Prevalence and risk factors of diabetic nephropathy among Thai patients with type2 diabetes mellitus. J Med Assoc Thai 2011;94(Suppl2):S1-S5
   Google Scholar
• Nitiyanant W, Chetthakul T, Sang-A-Kad P, et al. A survey study on diabetes management and complication status in primary care setting in Thailand. J Med Assoc Thai 2007;90:65-71
   PubMedGoogle Scholar
• Supapluksakul S, Ruamviboonsuk P, Chaowakul W. The prevalence of diabetic retinopathy in Trang province determined by retinal photography and comprehensive eye examination. J Med Assoc Thai 2008;91:716-22
   PubMedGoogle Scholar
• Chuengsamarn S, Rattanamongkolgul S, Jirawatnotai S. Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes. J Diabetes Complications 2014;28:124-9
   PubMed Web of Science ®Google Scholar
• Thaneerat T, Tangwongchai S. Prevalence of depression, hemoglobin A1c level, and associated factors in outpatients with type 2 diabetes. Asian Biomed (Res Rev News) 2009;3:383-90
   Google Scholar
• Rawdaree P, Sarinnapakorn V, Pattanaungkul S, et al. A prospective, longitudinal, multicenter, observational study to assess insulin treatment patterns in diabetic patients in Thailand: Results from the TITAN study. J Med Assoc Thai 2014;97:1140-50
   PubMedGoogle Scholar
• Swinnen S, Simon A, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011:CD006383
   PubMed Web of Science ®Google Scholar
• Swinnen S, Dain M, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33:1176-8
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home P, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16
   PubMed Web of Science ®Google Scholar
• Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009;25:542-8
   PubMed Web of Science ®Google Scholar
• Hollander P, Cooper J, Bregnhoi J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial cmparing insulin detemir with insulin glargine in a basal-bolous regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Long-acting insulin analogues for the treatment of diabetes mellitus: meta-analyses of clinical outcomes. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2008
   Google Scholar
• Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, et al. Long-term cost-effectiveness of insulin glargine versus neutral protamine Hagedorn insulin for type 2 diabetes in Thailand. Appl Health Econ Health Policy 2016;14:281-92
   PubMed Web of Science ®Google Scholar
• Drug and Medical Supply Information Center. 2015; April 15, 2016. http://dmsic.moph.go.th 2016 Apr 15
   Google Scholar
• Riewpaiboon A. Measurement of costs for health economic evaluation. J Med Assoc Thai 2014;97(Suppl5):S17-S26
   Google Scholar
• Jordan S, Lim L, Seubsman S, et al. Secular changes and predictors of adult height for 86105 male and female members of the Thai Cohort Study born between 1940 and 1990. J Epidemiol Commun Health 2012;66:75-80
   PubMed Web of Science ®Google Scholar
• Maharaj Nakorn Chiang Mai Hospital. Pharmacy and Healthcare Service Fees. Chiang Mai; 2014
   Google Scholar
• Pornpinatepong S. Cost-effectiveness analysis of diabetic retinopathy screening in type2 diabetes mellitus. Master’s Thesis. Bangkok: Mahidol University; 2005
   Google Scholar
• Riewpaiboon A. Standard cost lists for health technology assessment. Health Intervention and Technology Assessment Program (HITAP); 2011 Nonthaburi, Thailand
   Google Scholar
• Teerawattananon Y, Mugford M, Tangcharoensathien V. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health 2007;10:61-72
   PubMed Web of Science ®Google Scholar
• King Chulalongkorn Memorial Hospital. Pharmacy and Healthcare Service Fees. Bangkok: King Chulalongkorn Memorial Hospital; 2014
   Google Scholar
• National Health Security Office. Schedule of health benefits and fees. Bangkok: National Health Security Office; 2014.
   Google Scholar
• Bureau of Trade and Economics Indices, Ministry of Commerce. CPI 2016; July 8, 2016. www.price.moc.go.th/price/cpi/index_new_e.asp 2016 Jul 8
   Google Scholar
• Bank of Thailand. Rates of Exchange of Commercial Banks in Bangkon Metropolis (2002–present); January 7, 2016. http://www2.bot.or.th/statistics/ReportPage.aspx?reportID =123&language=eng 2016 Jan 7
   Google Scholar
• Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai 2014;97(Suppl5):S50-S8
   Google Scholar
• O’Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res 2002;11:455-68
   PubMed Web of Science ®Google Scholar
• Health Economic Working Group. The second meeting report of Health Economic Working Group in 2011. Bangkok: Food and Drug Administration, Ministry of Public Health; 2011
   Google Scholar
• Valentine W, Palmer A, Erny-Albrecht K, et al. Cost-effectiveness of basal insulin from a US Health System perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther 2006;23:191-207
   PubMed Web of Science ®Google Scholar
• Teerawattananon Y, Tritasavit N, Suchonwanich N, et al. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwesen 2014;108:397-404
   PubMedGoogle Scholar
• Freemantle N, Chou E, Frois C, et al. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open 2016;6:e009421
   PubMed Web of Science ®Google Scholar